Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of PTCT PTC Therapeutics | 130.4% in 12m

Compare PTCT with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare PTC Therapeutics with its related Sector/Index XBI

Compare PTC Therapeutics with its related Sector/Index XBI

Performance Duell PTCT vs XBI

TimeFrame PTCT XBI
1 Week 8.09% 0.35%
1 Month 14.6% 0.06%
3 Months 30.7% -1.76%
6 Months 32.2% 15.33%
12 Months 130.4% 48.94%
YTD 51.6% 9.31%
Rel. Perf. 1m 1.15
Rel. Perf. 3m 0.74
Rel. Perf. 6m 1.47
Rel. Perf. 12m 4.33
Spearman 1m 0.73 0.319
Spearman 3m 0.86 0.085

Is PTC Therapeutics a good stock to buy?

Neither. Based on ValueRay Fundamental Analyses, PTC Therapeutics is currently (October 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.26 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PTCT as of October 2024 is 53.90. This means that PTCT is currently undervalued and has a potential upside of +26.82% (Margin of Safety).

Is PTCT a buy, sell or hold?

  • Strong Buy: 6
  • Buy: 1
  • Hold: 6
  • Sell: 2
  • Strong Sell: 1
PTC Therapeutics has received a consensus analysts rating of 3.56. Therefor, it is recommend to hold PTCT.
Values above 0%: PTCT is performing better - Values below 0%: PTCT is underperforming

Compare PTCT with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 8.36% 13.16% 17.45% 90.84%
US NASDAQ 100 QQQ 7.24% 12.08% 16.31% 89.27%
US Dow Jones Industrial 30 DIA 9.68% 14.67% 21.23% 101.09%
German DAX 40 DAX 7.53% 17.07% 24.40% 98.42%
Shanghai Shenzhen CSI 300 CSI 300 9.41% 18.02% 21.52% 116.89%
Hongkong Hang Seng HSI 7.70% 17.72% 18.56% 117.68%
India NIFTY 50 INDA 8.72% 20.18% 27.07% 103.07%
Brasil Bovespa EWZ 7.70% 18.90% 40.45% 131.93%

PTCT PTC Therapeutics vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 7.47% 12.98% 16.10% 87.54%
Consumer Discretionary XLY 6.41% 14.34% 19.94% 96.93%
Consumer Staples XLP 8.51% 16.74% 23.75% 107.31%
Energy XLE 9.06% 12.25% 38.18% 122.04%
Financial XLF 8.15% 10.00% 15.53% 82.07%
Health Care XLV 9.76% 17.31% 25.45% 108.97%
Industrial XLI 10.24% 13.84% 21.52% 90.17%
Materials XLB 10.30% 16.81% 26.31% 103.30%
Real Estate XLRE 7.20% 14.74% 10.25% 92.10%
Technology XLK 8.85% 12.29% 17.11% 88.94%
Utilities XLU 8.85% 13.83% 9.68% 90.16%
Aerospace & Defense XAR 10.87% 12.91% 15.88% 91.02%
Biotech XBI 7.74% 14.50% 16.90% 81.41%
Homebuilder XHB 11.26% 19.80% 19.24% 64.93%
Retail XRT 8.92% 16.37% 27.11% 98.38%

PTCT PTC Therapeutics vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 10.62% 14.33% 43.64% 136.47%
Natural Gas UNG 7.41% 33.07% 42.76% 185.88%
Gold GLD 7.24% 9.20% 13.77% 90.80%
Silver SLV 9.19% 4.07% 5.81% 80.66%
Copper CPER 8.49% 17.70% 37.83% 109.91%

Returns of PTCT vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 8.46% 21.04% 26.89% 115.99%
iShares High Yield Corp. Bond HYG 7.93% 15.07% 25.62% 115.04%
Does PTC Therapeutics outperform its market, is PTCT a Sector Leader?
Yes, over the last 12 months PTC Therapeutics (PTCT) made 130.35%, while its related Sector, the SPDR S&P Biotech (XBI) made 48.94%.
Over the last 3 months PTCT made 30.69%, while XBI made -1.76%.
Period PTCT XBI S&P 500
1 Month 14.56% 0.06% 1.40%
3 Months 30.69% -1.76% 7.12%
12 Months 130.35% 48.94% 39.51%